Regulatory approvals, trial data, and major licensing deals in 2026 are accelerating subcutaneous biologics, cutting patient burden and reshaping biopharma strategy.
|Articles|November 16, 2022
Sanofi and Insilico Medicine Ink $1.2 Billion Drug Development Deal
Author(s)BioPharm International Editors
The deal will see Sanofi use Insilico’s AI drug discovery platform to advance up to six new drug development candidates.
Advertisement
Sanofi and Insilico Medicine, a clinical-stage biotechnology company, announced a multi-year strategic research collaboration on Nov. 8, 2022. The agreement will see Sanofi use Insilico’s AI platform, Pharma.AI, to advance drug development in up to six new targets.
According to a company press release, Sanofi will pay $21.5 million in upfront and target nomination fees. Additional payments for various research, development, and sales milestones reach as high as $1.2 billion, as well as mid-single to low double-digit tiered royalties for any products developed.
“We look forward to working with Insilico Medicine, a demonstrated leader in AI-powered drug discovery,” said Changchun Xiao, head of China Research, Sanofi, in the release.“This collaboration will leverage our complementary capabilities, as well as the co-location of our scientific teams, to boost the drug discovery efforts of the Sanofi Institute for Biomedical Research (SIBR), Sanofi’s R&D center in China.”
“We are very happy to collaborate with Sanofi, a company with a clear strategy in AI-powered drug discovery,” said Alex Zhavoronkov, CEO and founder, Insilico Medicine, in the release. “This close collaboration will allow Sanofi to immediately gain the capabilities of one of the top AI startups in addition to enriching their drug discovery pipeline."
Source: Insilico Medicine
Advertisement
Related to this article
Biocon's Pebrilzo, a pertuzumab biosimilar for HER2-positive breast cancer, has become the first monoclonal antibody biosimilar to receive a positive CHMP opinion under EMA's newly adopted tailored clinical approach, which can reduce comparative efficacy trial requirements.
Telix will acquire ITM for $1.65 billion, gaining a phase 3-validated therapy that cut GEP-NET progression risk versus everolimus.
mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
Dualitas will screen over 300,000 bispecific combinations for Roche, backing a deal worth up to $1 billion in immunology research.
GSK's new trispecific TCE targets 2 tumor antigens plus T cells, aiming to improve on the tolerability of current myeloma therapies.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Advertisement
Advertisement